KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab + Pertuzumab in HER2+ EBC

Slideset - Phase III investigation of neoadjuvant T-DM1 plus pertuzumab showed a favorable safety profile but lower clinical response rate compared with chemotherapy with trastuzumab plus pertuzumab in HER2-positive early breast cancer.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research